Abstract Details

Title Brain Tumor Reporting and Data System (BT-RADS) Score: A Novel Predictor of the Karnofsky Performance Scale and Progression-free Survival in Glioblastoma Patients

Topic Neuro-oncology

Presentation(s) P10 - Poster Session 10 (5:00 PM-6:00 PM)

Poster/Presentation
Number 6-014

Objective We aim to evaluate the Brain Tumor Reporting and Data System Score (BT-RADS) predictive value on functional outcomes assessed through the Karnofsky Performance Scale (KPS) and progression-free survival (PFS) in glioblastoma (GB) patients.

Background The BT-RADS is a novel eight-point classification system that standardizes magnetic resonance imaging (MRI) reporting in GB patients. While previous studies have demonstrated BT-RADS predictive value in the prognosis and overall survival of high-grade glioma patients, its association with functional outcomes and progression-free survival (PFS) in GB patients is unclear.

Design/Methods BT-RADS from MRI ~3 months post-diagnosis after chemo-radiation therapy (BT-RADS_A), and ~6 months post-diagnosis after the 6-month maintenance temozolomide (TMZ) cycle (BT-RADS_B) were analyzed. BT-RADS was classified as low (BT-RADS score 0-3a) and high (BT-RADS score 3b-4).

Results In a univariate logistic regression analysis, BT-RADS_A was a significant predictor (p=0.04) in discriminating an unfavorable KPS from a favorable one. In a multivariate logistic regression, in which the best model fit was the model containing BT-RADS_A and MGMT tumor status (model p value=0.03), the ROC analyses indicate that BT-RADS_A is not better than chance in differentiating an unfavorable KPS from a favorable one (model AUC=0.65; 95% CI=0.55, 0.76). The discriminatory ability of BT-RADS scores alone in predicting KPS outcomes was modest, as indicated by the AUC. This underscores the need for larger sample sizes. In a final model of BTRADS_A and BT-RADS_B, accounting for MGMT tumor status, the risk of tumor progression was 50% lower (p value=0.003) with a low BT-RADS (0-3a) in the BT-RADS _A group and 38% lower (p value=0.03) with a low BT-RADS (0-3a) in the BT-RADS_B group.

Conclusions Considering the above-discussed findings, BT-RADS may represent a new tool in the clinical management of glioblastoma patients by informing on disease progression, prognosis, and quality of life.

Authors/Disclosures
Michele Persico, MD PRESENTER	Dr. Persico has nothing to disclose.
Tsion Assaye, MD	Ms. Assaye has nothing to disclose.
Michael Essien, MBChB, MPH	Dr. Essien has nothing to disclose.
Brent D. Weinberg, MD, PhD	Dr. Weinberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Canon USA. Dr. Weinberg has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Avicenna.ai. Dr. Weinberg has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for multiple law firms.

��ɫ��

��ɫ��